Figure 3. HRs for cancer-specific mortality among PPI users stratified on patient and therapy.

Forest plots show adjusted HRs and 95% CIs for cancer-specific mortality among Danish cancer patients estimated using Cox proportional hazards regression model and stratified according to gender, age at diagnosis, Charlson Comorbidity Index (CCI) score, calendar year of diagnosis, registered cancer treatment (data available from 2002; note that the group “none registered” also include patients that have received oncological therapy, which has not been registered), number of post-diagnostic PPI prescriptions and type of PPI. Danish cancer patients with ≥2 prescriptions of PPIs 0-6 months after the cancer diagnosis were compared to nonusers (<2 prescriptions) of PPIs or users (≥2 prescriptions) of H₂RAs in the same period. Finally, as senitivity analyses, users with one prescription were compared to nonusers with no prescriptions 0-6 months after the cancer diagnosis.